Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
Head-to-head evidence comparison — which supplement is right for you?
Canakinumab vs Colchicine: they're closely matched on evidence (4 vs 3/10); they're alternatives for inflammation-related symptoms — the best pick depends on your goals. Take the 2-minute quiz for a pick tailored to your goals.
Canakinumab and Colchicine are closely matched across evidence, studies, and safety.
Verdict
Too few graded studies
1 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mixed
1 of 3 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Canakinumab and Colchicine have evidence — compare verdict strength side-by-side.
A prescription biologic, not self-administered for longevity. Approved CAPS dosing is 150 mg subcutaneously every 8 weeks (weight-adjusted in children). The CANTOS cardiovascular regimen was 150 mg subcutaneously every 3 months. There is NO established off-label longevity protocol, and cost is prohibitive.
Any time of day
Subcutaneous injection (clinician-administered)
A source-matched dose range is not available for this product and use.
If this treatment was prescribed for you, follow your prescriber’s directions. Do not change prescribed treatment because this page has no matched dose range.
Any time of day
Months to years
Weeks
Trial endpoints
Throughout use
Months to years
Weeks
Trial endpoints
Throughout use
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
The New England journal of medicine (2017) · RCT · n=10061
CANTOS: randomized, double-blind, placebo-controlled trial in ~10,000 post-MI patients with elevated hsCRP
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet (2017) · RCT
Exploratory analysis of the CANTOS cohort — incident and fatal lung cancer as pre-specified secondary endpoints
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Lung cancer (Amsterdam, Netherlands) (2024) · RCT · n=237
CANOPY-2: phase 3 randomized, double-blind trial in advanced non-small-cell lung cancer
Low-dose colchicine for secondary prevention of cardiovascular disease.
Journal of the American College of Cardiology (2013) · RCT · n=532
LoDoCo randomized trial of low-dose colchicine in stable coronary disease
Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
The New England journal of medicine (2019) · RCT
COLCOT randomized, placebo-controlled trial of colchicine 0.5 mg/day after MI
Colchicine for Secondary Prevention of Coronary Artery Disease: A Meta-Analysis of Randomised Controlled Trials.
Heart, lung & circulation (2022) · Meta-Analysis
Meta-analysis of colchicine trials for secondary cardiovascular prevention
Both Canakinumab and Colchicine are closely matched — the best choice depends on your specific health goals.
Both Canakinumab and Colchicine score equally (80) for inflammation-related symptoms.
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.